Hsbc Holdings PLC Buys New Position in Ingevity Corporation $NGVT

Key Points

• HSBC Holdings PLC initiated a position in Ingevity, purchasing 20,925 shares valued at approximately $1.57 million. Institutional investors collectively own 91.59% of NGVT.
• Ingevity exceeded quarterly earnings expectations, reporting $1.74 in EPS versus the $1.33 consensus and revenue of $314.1 million. The company provided fiscal 2026 EPS guidance of $5.00–$5.45.
• Analysts maintain a consensus “Hold” rating with an average price target of $80, while company insiders sold 17,801 shares worth about $1.35 million during the latest quarter.

Hsbc Holdings PLC bought a new stake in shares of Ingevity Corporation (NYSE:NGVT - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 20,925 shares of the company's stock, valued at approximately $1,568,000. Hsbc Holdings PLC owned about 0.06% of Ingevity at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in NGVT. Global Retirement Partners LLC purchased a new position in shares of Ingevity during the 4th quarter worth $27,000. Meeder Asset Management Inc. purchased a new stake in shares of Ingevity in the 4th quarter worth $33,000. Geneos Wealth Management Inc. increased its stake in shares of Ingevity by 85.8% in the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company's stock worth $36,000 after purchasing an additional 387 shares in the last quarter. Frazier Financial Advisors LLC bought a new position in Ingevity in the 2nd quarter worth $37,000. Finally, Headlands Technologies LLC bought a new position in Ingevity in the 2nd quarter worth $46,000. 91.59% of the stock is currently owned by institutional investors.

Ingevity Stock Performance

Shares of NYSE NGVT opened at $69.48 on Tuesday. The firm has a fifty day moving average price of $73.47 and a 200-day moving average price of $71.76. The company has a debt-to-equity ratio of 22.52, a current ratio of 1.61 and a quick ratio of 1.15. The stock has a market cap of $2.39 billion, a PE ratio of 47.27 and a beta of 1.16. Ingevity Corporation has a 1 year low of $45.85 and a 1 year high of $79.29.

Ingevity (NYSE:NGVT - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $1.74 EPS for the quarter, beating the consensus estimate of $1.33 by $0.41. Ingevity had a net margin of 4.65% and a return on equity of 284.70%. The firm had revenue of $314.10 million for the quarter, compared to the consensus estimate of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. Equities analysts anticipate that Ingevity Corporation will post 5.4 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Ingevity news, CEO David H. Li sold 5,000 shares of the firm's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $75.83, for a total transaction of $379,150.00. Following the sale, the chief executive officer directly owned 120,636 shares of the company's stock, valued at $9,147,827.88. This trade represents a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ryan C. Fisher sold 2,709 shares of the business's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $73.72, for a total value of $199,707.48. Following the completion of the transaction, the senior vice president owned 15,722 shares in the company, valued at $1,159,025.84. The trade was a 14.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 17,801 shares of company stock valued at $1,347,481 in the last quarter. 0.88% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Weiss Ratings raised Ingevity from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday, July 31st. Wall Street Zen downgraded Ingevity from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 1st. Two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, Ingevity presently has an average rating of "Hold" and an average price target of $80.00.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.

Want to see what other hedge funds are holding NGVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ingevity Corporation (NYSE:NGVT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.